Cargando…

COVID-19 rebound after oral treatment in a nursing home facility: A case series

Paxlovid (nirmatrevir/ritonavir) is a 2 drug regimen taken together twice daily for 5 days was authorized for emergency use for nonhospitalized patients who are at risk for the progression of coronavirus disease (COVID-19). However, recurrence of symptoms 2–8 days after completing the treatment cour...

Descripción completa

Detalles Bibliográficos
Autores principales:	Betrosian, Alex P., Christou, Stavros M., Kalathaki, Stavroula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd on behalf of Tsinghua University Press. 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664743/ https://www.ncbi.nlm.nih.gov/pubmed/38013912 http://dx.doi.org/10.1016/j.imj.2022.10.003

Ejemplares similares

To rebound or not to rebound
por: Stahl, Bethany A, et al.
Publicado: (2017)

COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature
por: Alshanqeeti, Shatha, et al.
Publicado: (2022)

Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation
por: González‐Suarez, Inés, et al.
Publicado: (2017)

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Pause at Your Own Peril: A Case Series on Rebound Pulmonary Hypertension
por: Murali, Sindhubarathi, et al.
Publicado: (2022)

An explanation for SARS-CoV-2 rebound after Paxlovid treatment
por: Perelson, Alan S., et al.
Publicado: (2023)

Managing rebound pain after regional anesthesia
por: Muñoz-Leyva, Felipe, et al.
Publicado: (2020)

PATIENT AND CAREGIVER PERCEPTIONS OF MOBILITY AFTER DISCHARGE FROM SKILLED NURSING FACILITIES TO HOME
por: Bankole, Ayomide, et al.
Publicado: (2022)

Comparing the Support-Efficacy Model among Centenarians Living in Private Homes, Assisted Living Facilities, and Nursing Homes
por: Randall, G. Kevin, et al.
Publicado: (2011)

The endosymbiont Wolbachia rebounds following antibiotic treatment
por: Gunderson, Emma L., et al.
Publicado: (2020)

STAFFING DIFFERENCES IN NURSING HOME SPECIAL FOCUS FACILITIES AND SPECIAL FOCUS FACILITY CANDIDATES
por: Rhodes, Annie, et al.
Publicado: (2022)

Factors associated with viral rebound among COVID-19 patients receiving oral antivirals
por: Chen, Pao-Yu, et al.
Publicado: (2023)

Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
por: Hurst, Jacob, et al.
Publicado: (2015)

Models of SIV rebound after treatment interruption that involve multiple reactivation events
por: van Dorp, Christiaan H., et al.
Publicado: (2020)

Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment
por: Charness, Michael E., et al.
Publicado: (2022)

Rebound Hypercalcemia After Denosumab Therapy in a Child With Cherubism
por: Litao, Melissa Kaori S, et al.
Publicado: (2021)

Home Health and Skilled Nursing Facility Use: 1982-90
por: Manton, Kenneth G., et al.
Publicado: (1994)

Facility Service Environments, Staffing, and Psychosocial Care in Nursing Homes
por: Zhang, Ning Jackie, et al.
Publicado: (2008)

Hepatitis Rebound after Infection with Yellow Fever Virus
por: Denis, Blandine, et al.
Publicado: (2019)

Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19
por: Birabaharan, Morgan, et al.
Publicado: (2022)

Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19
por: Zheng, Qian, et al.
Publicado: (2023)

Age-dependent rebound in asthma exacerbations after COVID-19 lockdown
por: Hazan, Guy, et al.
Publicado: (2022)

REBOUND COVID-19 AFTER PAXLOVID IN 2 RELATED FAMILY MEMBERS
por: Periyasamy, P., et al.
Publicado: (2023)

Left Atrial Thrombus Mimicking Myxoma Secondary to Rebound Hypercoagulable State
por: Niazi, Muhammad, et al.
Publicado: (2021)

To reuse or not reuse? That is a rebound question!
por: Akkara, John D, et al.
Publicado: (2023)

Rebound: a proven plan for starting over after job loss
por: Finney, Martha I
Publicado: (2009)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Rebound and Spillovers: Prosumers in Transition
por: Dütschke, Elisabeth, et al.
Publicado: (2021)

Healthcare Cost Reductions after Moving into a Wet Nursing Home Stay—A Case Series
por: Thiesen, Henrik, et al.
Publicado: (2017)

The Physical Environment of Nursing Homes for People with Dementia: Traditional Nursing Homes, Small-Scale Living Facilities, and Green Care Farms
por: de Boer, Bram, et al.
Publicado: (2018)

Facility characteristics as independent prognostic factors of nursing home-acquired pneumonia
por: Lim, Che Wan, et al.
Publicado: (2016)

THE QUALITY OF DENTAL CARE IN NURSING HOMES: VARIATION BY FACILITY AND MARKET CHARACTERISTICS
por: Ye, Zhiqiu, et al.
Publicado: (2019)

Not as simple as it seems: extensive facility and training gaps in nursing home bathing
por: Nguyen, Kristine P., et al.
Publicado: (2023)

Not as simple as it seems: Extensive facility and training gaps in nursing home bathing
por: Nguyen, Kristine, et al.
Publicado: (2023)

Heritability of heart rate recovery and vagal rebound after exercise
por: Nederend, Ineke, et al.
Publicado: (2016)

Facility Characteristics and Quality Deficiencies of Florida Nursing Homes With COVID-19 Cases and Deaths
por: Wang, Xiaochuan, et al.
Publicado: (2020)

Managing the Impact of COVID-19 in Nursing Homes and Long-Term Care Facilities: An Update
por: Dyer, Adam H., et al.
Publicado: (2022)

Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation
por: Antonelli, Guido, et al.
Publicado: (2022)

Clinical features of COVID-19 patients with rebound phenomenon after corticosteroid therapy
por: Murakami, Koji, et al.
Publicado: (2022)

COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022
por: Wang, Lindsey, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lk4d66di0h637dp4fo47u9fdk4